

# PHYTIC ACID AND VITAMIN B6 COMPOSITIONS AND THEIR APPLICATION IN PATHOLOGICAL AND PRE-PATHOLOGICAL CONDITIONS RESULTING FROM THE FORMATION OF AGE<sub>s</sub> PRODUCTS IN DIABETES

INVENTORS: Servei de Salut de les Illes Balears; Universitat de les Illes Balears

## HIGHLIGHTS

- ✓ Preventive therapy of AGE<sub>s</sub> formation in patients with DM
- ✓ Different ways of administration

## TECH STATUS

- ✓ TRL5
- ✓ PATENT Priority numbers: ES2596752B1
- ✓ Priority date: 10 July 2015

## Problem to be solved

The present invention shows a high benefit in patients with DM, a disease that leads to the development of many metabolic disorders, such as AGE formation. The use of phytic acid compositions alone or in conjunction with vitamin B6 to inhibit the development of AGE<sub>s</sub> has been studied.

## Background and Technology

A research and clinical team specialized in vascular and metabolic diseases has discovered a novel therapy which with the administration or supplementation of phytate alone or combined with vitamin B6 in patients with DM, a decrease in HbA1c levels and AGE<sub>s</sub> was observed due to the inhibition of

protein glycosylation and the following metabolic cascade.

## Applications

The invention could be applied in the prevention and/or treatment in patients with DM and who present the following complications in protein glycosylation, ending in the development of AGE<sub>s</sub>.

This novel treatment has been tested in 40 patients with great benefits.

## Contact Information:

[carlos.enrique@ssib.es](mailto:carlos.enrique@ssib.es) – Health Research Institute of the Balearic Islands (IdISBa)

## Technology status

Clinical trials performed into 40 patients with no serious adverse effects:

- Between the control group and the supplemented group, a decrease in AGEs of approximately 10% was observed.

### **Patent Application number:**

EP3320905A4 / US2018214463A1

PCT application No: WO2017/009506

**Title:** Phytic acid and vitamin B6 compositions and their application in pathological and pre-pathological conditions resulting from the formation of advanced glycation products in diabetic patients.

Collaboration between two applicants: Servei de Salut de les Illes Balears and Universitat de les Illes Balears.

## Market Opportunity

### **Transferred.**

The patent was licensed to Devicare S.L. in November 2017 after a search for companies interested in the technology.